机构：[1]Sichuan Canc Hosp & Inst, Chengdu, Peoples R China四川省肿瘤医院[2]China Med Univ, Shengjing Hosp, Shenyang, Peoples R China中国医科大学附属盛京医院中国医科大学盛京医院[3]Chongqing Univ Canc Hosp, Chongqing, Peoples R China[4]Chongqing Canc Inst, Chongqing, Peoples R China[5]Chongqing Canc Hosp, Chongqing, Peoples R China[6]Yunnan Canc Hosp, Kunming, Yunnan, Peoples R China[7]Chengdu Mil Gen Hosp, Chengdu, Peoples R China[8]Amoy Diagnost Co LTD, Xiamen, Peoples R China[9]Jining Med Univ, Affiliated Hosp, Jining, Peoples R China[10]Jiangnan Univ, Affiliated Hosp, Wuxi, Jiangsu, Peoples R China[11]Nanjing Med Univ, Affiliated Wuxi Peoples Hosp, Wuxi, Jiangsu, Peoples R China[12]Xi An Jiao Tong Univ, Hlth Sci Ctr, Affiliated Hosp 1, Xian, Peoples R China[13]Fuzhou Gen Hosp, Nanjing Mil Command, Fuzhou, Peoples R China[14]Shanxi Med Univ, Shanxi Canc Hosp & Inst, Taiyuan, Peoples R China[15]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
第一作者机构：[1]Sichuan Canc Hosp & Inst, Chengdu, Peoples R China
推荐引用方式(GB/T 7714)：
Liu Yang,Yang Xianghong,Li Yu,et al.A novel algorism evaluating dominant clonality in Chinese NSCLC patients with concomitant EGFR and ALK variation[J].CANCER RESEARCH.2021,81(13):doi:10.1158/1538-7445.AM2021-3136.
APA：
Liu, Yang,Yang, Xianghong,Li, Yu,Zhou, Yongchun,Chen, Yihua...&Han, Yuchen.(2021).A novel algorism evaluating dominant clonality in Chinese NSCLC patients with concomitant EGFR and ALK variation.CANCER RESEARCH,81,(13)
MLA：
Liu, Yang,et al."A novel algorism evaluating dominant clonality in Chinese NSCLC patients with concomitant EGFR and ALK variation".CANCER RESEARCH 81..13(2021)
医学